FDA Brief

Warning letters Drugs

FDA warning letter to

Luis Javier Pena-Hernandez, M.D., FCCP

High riskIssued Sep 20, 2023Posted Sep 29, 2023Center for Drug Evaluation and Research | CDER

FDA warns Dr. Pena-Hernandez over ineligible subject enrollment and lapsed IRB approval for investigational drugs.

What happened

FDA inspected Dr. Pena-Hernandez’s clinical site from January 9 to January 23, 2023, as part of its Bioresearch Monitoring Program. FDA found that one subject did not meet a protocol inclusion criterion requiring current use of a specified drug but was randomized, and that IRB approval lapsed from December 3, 2021, to January 27, 2022, while study visits and procedures were performed. FDA also said his written responses did not provide enough detail on corrective actions.

What FDA found

  1. Failed to ensure the investigation was conducted according to the investigational plan; a subject was randomized even though records did not show the protocol-required current use of a specified drug.

    21 CFR 312.60
  2. Failed to ensure an IRB compliant with 21 CFR part 56 reviewed and approved the study; IRB approval lapsed from December 3, 2021, to January 27, 2022, while study visits and procedures occurred.

    21 CFR 312.66

What FDA wants

Within 15 business days of receipt, notify FDA in writing of actions taken to prevent similar violations; failure to adequately address the matter may lead to regulatory action.

Who should pay attention

  • clinical research sites and investigators
  • sponsors and contract research organizations relying on investigator oversight
  • IRBs and research compliance teams

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Stephen J. Fallon, Ph.D.

    FDA warns clinical investigator Stephen J. Fallon, Ph.D. over consent and record failures in an HIV self-test study.

    High risk
  2. Adnan Dahdul, MD

    FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.

    High risk
  3. Center For Immunology Science, LLC

    FDA cites Center for Immunology Science for a clinical trial of heat-killed Mycobacterium smegmatis without an Investigational New Drug application.

    High risk
  4. Prodrome Sciences USA, LLC

    Prodrome Sciences studied its supplement ProdromeNeuro Oil as a dementia drug in 29 people without first filing an IND, FDA says.

    High risk